A Netflix executive has filed a wrongful termination lawsuit after being dismissed from his position following disclosure of ketamine treatment for clinical depression. The employee, David Baillie, claims he took the substance under medical supervision as part of legitimate therapeutic care. The case raises important questions about workplace discrimination, mental health stigma, and employee rights regarding medical treatments. It highlights tension between corporate culture and individual health needs in the tech industry.

Summary auto-generated by AI from the original publisher's content. Editorial standards.